Altimmune, Inc.

NASDAQ:ALT

Biotechnology

Healthcare
$1.39 +3.09%

+$0.08 today

Market cap
$270.48M
Beta
0.23
P/E (TTM)
-3.7
EPS (TTM)
-$0.73
52W Low $2.56High $7.73

Volume 4.69M

Average 3.81M

ALT Interest Expense

Cost of servicing the company's debt during the period.

Altimmune, Inc.NASDAQ: ALT

Interest Expense · Q1 FY2026 · quarter ended Mar 2026

Interest expense growth accelerates

Q1 FY2026 interest expense of $1.07M rose 106700.0% year over year, ahead of the +29933.3% change in trailing-twelve-month interest expense. Sequentially, it rose 21.9% from the prior quarter. Over 3 fiscal years it compounded at +489.2% a year.

Context

  • Interest expense amounted to 3990.2% of revenue in FY2025, up 3945.2 pp from a year earlier.
  • Interest expense increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +106700.0% holds above the trailing-twelve-month pace of +29933.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.07M+21.9% QoQ
Last fiscal yearDec 2025
$1.64M+18077.8% YoY
LTMMar 2026
$2.7M+29933.3% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+106700.0%——
1 year+18077.8%——
3-year CAGR+489.2%——
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
1.64M USD
Year-over-year change
+18077.8%
4-year CAGR
+325.3%

Interest Expense vs competitors

How ALT compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +29933.3% is the highest of 4, against a peer median of +20.8%.
  • Interest expense amounts to 7508.3% of revenue for ALT, versus a peer median of 0.0%.
ALT Competitors
Interest Expense for ALT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IVAInventiva S.A.FY2025€32.3M EUR+165.2%+257.5%720.4%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$10.4M USD+20.8%—15.0%
ALTAltimmune, Inc.LTM Mar 2026$2.7M USD+29933.3%+489.2%7508.3%
ABUSArbutus Biopharma CorporationLTM Mar 2026$86K USD-28.9%-61.7%0.0%
VIRVir Biotechnology, Inc.LTM Mar 2026$0 USD——0.0%
GPCRStructure Therapeutics Inc.LTM Jun 2026$0 USD———
ASMBAssembly Biosciences, Inc.LTM Mar 2026$0 USD——0.0%
INDPIndaptus Therapeutics, Inc.LTM Mar 2026$0 USD———
BMEABiomea Fusion, Inc.LTM Mar 2026$0 USD———
Peer median (excluding ALT) —+20.8%+97.9%0.0%

Competitors are the stored peer set for ALT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.41M(68K)426K20K41K
Cost of Revenue00000
Gross Profit4.41M(68K)426K20K41K
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development74.54M70.54M65.8M82.23M66.43M
Selling, General & Admin15.41M17.13M18.14M20.97M28.1M
Operating Expenses101.32M87.67M96.36M103.19M94.53M
Depreciation & Amortization551K493K477K238K112K
EBITDA(96.53M)(84.41M)(87.94M)(94.81M)(87.03M)
EBITDA Margin-2189.0%124130.9%-20642.0%-474060.0%-212258.5%
Operating Income(96.91M)(87.74M)(95.93M)(103.17M)(94.49M)
Operating Margin-2197.6%129029.4%-22518.5%-515860.0%-230461.0%
Interest Income203K2.87M7.35M8.07M7.54M
Interest Expense5K8K35K9K1.64M
Other Income / Expenses(176K)2.83M7.48M8.11M5.72M
Income Before Tax(97.09M)(84.91M)(88.45M)(95.06M)(88.77M)
Pre-Tax Margin-2201.6%124867.6%-20762.2%-475295.0%-216522.0%
Income Tax Expense0(197K)00(681K)
Net Income(97.09M)(84.71M)(88.45M)(95.06M)(88.09M)
Net Margin-2201.6%124577.9%-20762.2%-475295.0%-214861.0%
EPS (Basic)(2.35)(1.81)(1.66)(1.34)(1.00)
EPS (Diluted)(2.35)(1.81)(1.66)(1.34)(1.00)
Weighted Avg Shares41.28M46.93M53.25M71M88.1M
Weighted Avg Shares (Diluted)41.28M46.93M53.25M71M88.1M

Altimmune, Inc.

NASDAQ:ALT

Intrinsic Alpha fair value

Locked

Current Price

$1.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.